Skip to main content
Everest Medicines Limited (HKG:1952)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
35.34
-0.32 (-0.90%)
Apr 29, 2026, 4:08 PM HKT

Everest Medicines Revenue

In the year 2025, Everest Medicines had annual revenue of 1.71B CNY with 141.51% growth. Everest Medicines had revenue of 1.26B in the half year ending December 31, 2025, with 977.06% growth.

Revenue
1.71B CNY
Revenue Growth
+141.51%
P/S Ratio
6.54
Revenue / Employee
2.10M CNY
Employees
812
Market Cap
12.42B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.71B1.00B141.51%
Dec 31, 2024706.68M580.75M461.16%
Dec 31, 2023125.93M113.14M884.46%
Dec 31, 202212.79M12.74M23,588.89%
Dec 31, 202154.00K--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
CARsgen Therapeutics Holdings 139.84M
HBM Holdings 1.23B
Alphamab Oncology 630.11M
Lepu Biopharma 1.04B
CStone Pharmaceuticals 299.99M
Abbisko Cayman 681.17M
Shanghai Haohai Biological Technology 2.73B
Nanjing Leads Biolabs 197.25M
Revenue Rankings

Everest Medicines News

More News